Accueil>>Natural Products>>Gypenoside XLVI

Gypenoside XLVI

Catalog No.GC36206

Le gypénoside XLVI est l'une des principales saponines triterpénoÏdes de type dammarane de Gynostamma pentaphallum. Le gypenoside XLVI a une structure triterpénique tétracyclique et possède une puissante activité inhibitrice des cellules du carcinome pulmonaire non À petites cellules A549.

Products are for research use only. Not for human use. We do not sell to patients.

Gypenoside XLVI Chemical Structure

Cas No.: 94705-70-1

Taille Prix Stock Qté
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum[1]. Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity[2].

[1]. Zheng Y , et al. Gynosaponin TN-1 producing from the enzymatic conversion of gypenoside XLVI by naringinase and its cytotoxicity on hepatoma cell lines. Food Chem Toxicol. 2018 Sep;119:161-168. [2]. Zhang L , et al. Simultaneous determination of gypenoside LVI, gypenoside XLVI, 2α-OH-protopanaxadiol and their two metabolites in rat plasma by LC-MS/MS and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Nov 15;1005:9-16.

Avis

Review for Gypenoside XLVI

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Gypenoside XLVI

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.